Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 12:31 PM
Ignite Modification Date:
2025-12-24 @ 12:31 PM
NCT ID:
NCT04223661
Brief Summary:
The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
Detailed Description:
This is a multi-institution, prospective, single arm Phase II trial of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite) with no blinding or randomization. This study will enroll 44 patients over 36 months.
Primary Objectives:
1. Evaluate Response rate
2. Evaluate Side effects
Secondary Objectives:
1. Evaluate Time on therapy
2. Evaluate Progression free survival
3. Evaluate Time to the next line of therapy
4. Assess Quality of life
Study:
NCT04223661
Study Brief:
Protocol Section:
NCT04223661